It comes mainly because no surprise, after that, that activating mutations in the gene occurring in tumor cells have an identical clinical impact to gene mutations, building them refractory both to cetuximab and panitumumab [6, 27, 45C47]
It comes mainly because no surprise, after that, that activating mutations in the gene occurring in tumor cells have an identical clinical impact to gene mutations, building them refractory both…